F-PSMA-N5
Phase 1Small molecule
F-PSMA-N5 is one of 53 small molecule programs targeting Metastasis. It is currently in Phase 1.
1
Indications
2
Total Trials
2
Active Trials
52
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
64 competitors in Metastasis
#DrugCompanyPhaseTrials
1Camptosar
PfizerApproved
Gemzar
Johnson & JohnsonApproved
Norvir
AbbVieApproved
Neoral
NovartisApproved
Lynparza
AstraZenecaApproved
Tukysa
PfizerApproved
Taxol
TevaApproved
Trexall
Jazz PharmaceuticalsApproved
Femara
NovartisApproved
Keytruda
Merck & Co.Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Metastasis2 trials
Head-to-head Comparison of [18F]F-PSMA-N5 With [18F]F-PSMA-1007 PET/CT in PCa Diagnosis, Recurrence, and Metastasis
Recruiting·—·Phase 1·NCT06462495·30 enrolled
Head-to-head Comparison of [18F]F-PSMA-N5 With [68Ga]Ga-PSMA-11 PET/CT in PCa Diagnosis, Recurrence, and Metastasis
Recruiting·—·Phase 1·NCT06462508·30 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for F-PSMA-N5. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- AAnhui Provincial Hospital